Latest revenue
$39.0K
as of 2026-03-31
Latest net income
$-4.4M
as of 2026-03-31
Net margin
-11156.4%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $54.5M
- Enterprise value
- $54.5M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $1.89
- 52-wk low
- $0.36
- Beta
- —
- Shares out
- 76.9M
5-year trend
What this company does
ITEM 1. Business Unless otherwise noted or the context otherwise requires, all references in this section to “Envoy Medical,” “we,” “us” or “our” refer to Envoy Medical, Inc. following the Business Combination, other than certain historical information which refers to the business of Legacy Envoy prior to the consummation of the Business Combination. Overview We are a hearing health company focused on providing innovative medical technologies across the hearing loss spectrum. Our technologies are designed to shift the paradigm within the hearing industry and bring both providers and patients the hearing devices they desire. We are dedicated to pushing beyond the status quo to provide…
AI summary unavailable — showing raw filing excerpt
Generated from COCH's filing dated 2026-03-23
Key risks
ITEM 1A. Risk Factors An investment in our securities involves substantial risks. In addition to other information in this Annual Report on Form 10-K, you should carefully consider the risks described in this Report, as well as other information and data set forth in this Report, before making an investment decision with respect to our securities. The occurrence of any of such risks could materially and adversely affect our business, prospects, financial condition and results of operations, which could cause you to lose all or a part of your investment in our securities. Some statements in this Report constitute forward-looking statements. See “Cautionary Note Regarding Forward-Looking…
AI summary unavailable — showing raw filing excerpt
Generated from COCH's filing dated 2026-03-23
Profitability
Operating margin
-9240.7%
8.0%Net margin
-9857.3%
6.7%Return on equity
195.4%
77.0%Return on assets
-277.6%
54.0%Leverage
Debt / equity
-1.70×
5.7%Long-term debt / equity
-0.99×
9.2%Debt / assets
242.1%
8.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $39.0K | -15.2% | $-4.4M | +12.9% | -11156.4% |
Q4 2025 2025-12-31 | $75.0K | +78.6% | $-6.6M | -42.6% | -8781.3% |
Q3 2025 2025-09-30 | $42.0K | -25.0% | $-6.5M | -8.8% | -15433.3% |
Q2 2025 2025-06-30 | $78.0K | +14.7% | $-5.7M | -44.2% | -7294.9% |
Q1 2025 2025-03-31 | $46.0K | -22.0% | $-5.0M | +20.3% | -10865.2% |
Q4 2024 2024-12-31 | $42.0K | — | $-4.6M | — | -10995.2% |
Q3 2024 2024-09-30 | $56.0K | -30.0% | $-6.0M | -481.3% | -10642.9% |
Q2 2024 2024-06-30 | $68.0K | +7.9% | $-3.9M | -838.5% | -5804.4% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Orthopedic, Prosthetic & Surgical Appliances & Supplies · SIC 3842
Your notes
Keep private notes on COCH — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$8.2M
Insider selling
$0
Net activity
+$8.2M
Distinct insiders
6
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns COCH
Institutional value
$1.5M
Total shares held
2.3M
Distinct holders
18
-9 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 881.7K | $586.3K | — | New |
| 2 | DSG Capital Advisors, LLC | 625.0K | $415.7K | — | New |
| 3 | VANGUARD FIDUCIARY TRUST CO | 294.7K | $196.0K | — | New |
| 4 | Arcus Capital Partners, LLC | 187.6K | $124.8K | +0 (+0.0%) | No change |
| 5 | CIBC Bancorp USA Inc. | 77.9K | $51.8K | — | New |
| 6 | UBS Group AG | 70.5K | $46.9K | +45.0K (+177.2%) | Added |
| 7 | BlackRock, Inc. | 47.5K | $31.6K | +7.6K (+19.1%) | Added |
| 8 | Lantern Wealth Advisors, LLC | 30.0K | $20.0K | — | New |
| 9 | LPL Financial LLC | 28.4K | $18.9K | +0 (+0.0%) | No change |
| 10 | AFG FIDUCIARY SERVICES LIMITED PARTNERSHIP | 12.0K | $8.5K | — | New |
| 11 | BlueStem Wealth Partners, LLC | 10.5K | $7.0K | +0 (+0.0%) | No change |
| 12 | Ballew Advisors, Inc | 10.1K | $6.6K | +0 (+0.0%) | No change |
| 13 | Vanguard Global Advisers, LLC | 3.8K | $2.5K | — | New |
| 14 | Farther Finance Advisors, LLC | 3.0K | $2.1K | +0 (+0.0%) | No change |
| 15 | American Capital Advisory, LLC | 2.0K | $1.3K | +0 (+0.0%) | No change |
| 16 | WELLS FARGO & COMPANY/MN | 1.7K | $1.2K | +0 (+0.0%) | No change |
| 17 | CITIGROUP INC | 215 | $143 | +214 (+21400.0%) | Added |
| 18 | GSA CAPITAL PARTNERS LLP | 12.6K | $8 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once COCH's latest filing finishes processing.